Zobrazeno 1 - 10
of 27
pro vyhledávání: '"William Tracewell"'
Autor:
Holger Scheible, Martin Dyroff, Annick Seithel‐Keuth, Eleanor Harrison‐Moench, Nadra Mammasse, Andreas Port, Angelika Bachmann, Jennifer Dong, Jan Jaap vanLier, William Tracewell, David Mitchell
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2420-2430 (2021)
Abstract The highly selective, covalent Bruton’s tyrosine kinase inhibitor evobrutinib is under investigation for treatment of patients with multiple sclerosis (MS). Early clinical studies in healthy participants and patients with relapsing MS indi
Externí odkaz:
https://doaj.org/article/489421b638da46dbad0cbcea83c71c6e
Autor:
George Bailey, David Williams, Kenneth Turteltaub, William Tracewell, Cliff Pereira, Roderick Dashwood, Graham Bench, John Mata, Carole Jubert
Perspective on this Article from Effects of Chlorophyll and Chlorophyllin on Low-Dose Aflatoxin B1 Pharmacokinetics in Human Volunteers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::363d2e568d19e71fc5e7b37cb903bdda
https://doi.org/10.1158/1940-6207.22523403.v1
https://doi.org/10.1158/1940-6207.22523403.v1
Autor:
Eleanor Harrison-Moench, Jan J. van Lier, Jennifer Dong, Angelika Bachmann, David Mitchell, Andreas Port, Nadra Mammasse, Annick Seithel-Keuth, Martin Dyroff, William Tracewell, Holger Scheible
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2420-2430 (2021)
Clinical and Translational Science
Clinical and Translational Science
The highly selective, covalent Bruton’s tyrosine kinase inhibitor evobrutinib is under investigation for treatment of patients with multiple sclerosis (MS). Early clinical studies in healthy participants and patients with relapsing MS indicated tha
Autor:
Hooman Beygi, Igor D. Grachev, Juha-Matti Savola, Micha Levi, Serge Guzy, Margaret Bradbury, Pippa S. Loupe, Lavi Erisson, Ofer Spiegelstein, Maria Velinova, Spyros Papapetropoulos, William Tracewell, Mirna McDonald, Orit Cohen-Barak, Frank Schneider
Publikováno v:
British Journal of Clinical Pharmacology. 84:2422-2432
AIMS SD-1077, a selectively deuterated precursor of dopamine (DA) structurally related to L-3,4-dihydroxyphenylalanine (L-DOPA), is under development for treatment of motor symptoms of Parkinson's disease. Preclinical models have shown slower metabol
Autor:
William Tracewell, Murray P. Ducharme, Mona Darwish, Laura Rabinovich-Guilatt, Sally Selim, Philippe Colucci, Ofer Spiegelstein, Richard Malamut, Ronghua Yang, Mary Bond, Philmore Robertson
Publikováno v:
Clinical Drug Investigation. 37:1153-1163
Food intake can alter the pharmacokinetics of certain medications, including changes in their oral bioavailability, which is of particular concern for extended-release (ER) opioids because of the high drug loads. Two randomized, open-label studies as
Publikováno v:
Pain Medicine: The Official Journal of the American Academy of Pain Medicine
Objective. To compare the oral abuse potential of hydrocodone extended-release (ER) tablet developed with CIMA® Abuse-Deterrence Technology with that of hydrocodone immediate release (IR). Design. Randomized, double-blind, placebo-controlled, crosso
Publikováno v:
Clinical Pharmacology in Drug Development. 5:141-149
Two open-label, single-dose, parallel-group studies assessed effects of renal and hepatic impairment on the pharmacokinetics of a hydrocodone extended-release (ER) formulation developed with the CIMA Abuse-Deterrence Technology platform. Forty-eight
Publikováno v:
Clinical Drug Investigation
Background Greater drug content requirements for extended-release (ER) opioids necessitate greater protection against dose dumping. Hydrocodone ER employs the CIMA® Abuse-Deterrence Technology platform, which provides resistance against rapid releas
Publikováno v:
Clinical Drug Investigation. 35:13-22
A hydrocodone extended-release (ER) formulation employing the CIMA® Abuse-Deterrence Technology platform was developed to provide resistance against rapid release of hydrocodone when tablets are comminuted or taken with alcohol. This study evaluated
Publikováno v:
Clinical Drug Investigation. 30:365-373
Background: Fentanyl buccal tablet (FBT) is indicated for the treatment of breakthrough pain in patients who are already receiving, and who are tolerant to, opioid therapy for underlying, persistent cancer pain. Breakthrough pain may be severe or exc